In a landmark move to strengthen global oncology collaboration, Zhejiang Cancer Hospital (ZJCH) and Charité Comprehensive Cancer Center (CCCC) in Germany officially signed a strategic cooperation agreement during a ceremony held in Berlin on May 12. The signing, witnessed by senior leaders from both institutions and representatives from the Chinese Embassy in Germany, paves the way for joint efforts in cancer research, talent development, and patient care innovation.
ZJCH’s President Prof. Cheng Xiangdong and Prof. Ulrich Keilholz, Director of Charité CCCC, inked the agreement to address high-incidence cancers in China and Germany through shared research projects, cross-border clinical training, and technology transfer.
Ahead of the signing, ZJCH hosted a talent recruitment seminar at Charité’s Mitte Campus on May 11, where Prof. Cheng outlined ZJCH’s “Talent-Driven Development” strategy to attract global professionals. Discussions with overseas scholars focused on career opportunities in ZJCH’s cutting-edge programs, reinforcing its commitment to internationalizing medical research.
The collaboration gained further momentum during the delegation’s visit to the Chinese Embassy in Germany, where ZJCH leaders and Education Office First Secretary Pan Mengqiu explored frameworks for sustaining youth talent exchanges and deepening Sino-German medical diplomacy.
This alliance aligns with broader initiatives by Zhejiang Association for Science and Technology and Charité Medical University, aiming to set new benchmarks in cancer care through resource integration and knowledge sharing.
About the Insititute
Charité Comprehensive Cancer Center (CCCC) is a cornerstone of Berlin’s Charité Medical University (founded 1710), Europe’ s largest oncology hub, operating across four campuses with 23,000+ staff and 3,293 beds. Consistently ranked among Newsweek’s top global hospitals, it integrates cutting-edge research, clinical care, and education. The center pioneers precision oncology, immunotherapy, and multinational trials, focusing on high-incidence cancers like lung and breast malignancies. Its interdisciplinary model bridges 17 oncology departments and 100+ research groups, driving breakthroughs from lab to bedside. A leader in training next-gen oncologists, CCCC also spearheads global partnerships to advance equitable cancer care and innovation.